Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
21-40 of 998 trials

Xenon Treatment for Brain Injury After Aneurysmal Subarachnoid Hemorrhage

We are investigating whether xenon gas can help protect the brain and improve recovery in patients who have experienced a specific type of brain bleed. This study will also look at the safety and effects of xenon on neurological outcomes.

Aneurysmal Subarachnoid Hemorrhage6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Chronic Kidney Disease: Amiloride Treatment Study

We are investigating whether the diuretic amiloride can help protect kidney function in people with chronic kidney disease. The study looks at its effects on kidney health and inflammation.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Geographic Atrophy: JNJ-81201887 Treatment Study

We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.

Geographic Atrophy>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteOphthalmology

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Hematological MalignancyConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Eosinophilic Gastritis: Dupilumab Treatment Study

We are investigating how well dupilumab works for adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. The study will also look at the safety and side effects of this treatment.

Eosinophilic Gastritis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Multiple MyelomaEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Aspirin for Preventing Preeclampsia in First-Time Pregnant Women

We are studying whether daily aspirin can help prevent preeclampsia and improve pregnancy outcomes in women who are pregnant for the first time after assisted reproductive technology. This trial compares aspirin to a placebo to see which is more effective.

Preeclampsia>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteGynecology and Obstetrics

Esophageal Cancer Treatment: The NEEDS Trial

We are comparing two treatment methods for operable esophageal squamous cell carcinoma to see which may help patients survive longer. The study also examines quality of life and other health impacts during and after treatment.

Locally Advanced Esophageal Squamous Cell Carcinoma≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNephrologyRheumatology

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: REGN7075 with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining REGN7075 and cemiplimab for patients with advanced cancers. This trial aims to explore how well this combination works and its impact on patients' quality of life.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology